Key stats
About Global X Genomics & Biotechnology ETF
Expense ratio
0.50%
Home page
Inception date
Apr 5, 2019
GNOM is Global Xs take on biotech, with more of an emphasis on genomics specifically. The fund fleshes out its description of this sector by including companies that derive more than 50% of their revenues from the following five business activities: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology. The fund uses a proprietary natural language processing algorithm to identify and rank eligible firms based on public documents, such as filings and disclosures. Holdings may span the market-cap spectrum and come from across the globe, including some emerging markets. The market-cap-weighted index is reconstituted and rebalanced semi-annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.94%
Health Technology99.21%
Health Services0.73%
Bonds, Cash & Other0.06%
Cash0.05%
Miscellaneous0.01%
Stock breakdown by region
North America97.27%
Asia2.73%
Latin America0.00%
Europe0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history